A groundbreaking study led by Professor Takuya Takahashi reveals a significant connection between elevated AMPA receptor density and cognitive symptoms in Long COVID patients. This finding could lead to new diagnostic and treatment strategies.
Gisèle Pelicot faces one of her attackers in court, a year after 51 were convicted in a landmark case. As France grapples with the aftermath, opinions in her hometown reveal a complex legacy of the trial.
In Manchester, scientists are divided over the implications of 'mirror life' research, which could lead to synthetic cells with mirror-image molecules. While some see potential benefits, others warn of significant health and environmental risks.
Discover the inspiring journey of Jim Czirr, former Michigan football star, as he transitions from battling legends on the field to fighting cancer through groundbreaking drug development.
In a highly anticipated match, Emma Raducanu and Carlos Alcaraz's doubles partnership was swiftly defeated by the top-seeded duo of Jessica Pegula and Jack Draper, who are now on a winning streak in the US Open.
In a dramatic turn of events, Nicholas Alahverdian, who faked his death to escape sexual assault charges, was convicted of rape in Utah. The survivor's brave testimony led to justice. Sentencing is set for October 20.
In a surprising move, the US Department of Health has canceled contracts worth $500 million related to mRNA vaccine research, sparking concerns about future pandemic preparedness and the direction of vaccine technology.
In a surprising turn of events, the FDA has allowed Sarepta Therapeutics to resume shipments of its gene therapy, Elevidys, for younger Duchenne muscular dystrophy patients who can walk, despite concerns over previous fatalities.
As gene therapy for Duchenne muscular dystrophy faces scrutiny after tragic deaths, families like the Revells navigate the uncertain waters of hope and risk, questioning the future of their loved ones.
Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy is on hold due to safety issues. An FDA official warns the path to market approval is fraught with challenges, especially after patient deaths linked to liver injuries.
